

Epioxa® Billing and Coding

Quick Reference Guide



This guide provides a streamlined overview of codes commonly associated with keratoconus and epithelium-on corneal crosslinking treatment with Epioxa HD (riboflavin 5'-phosphate ophthalmic solution) 0.239% and Epioxa (riboflavin 5'-phosphate ophthalmic solution) 0.177%. The codes listed are not exhaustive and are intended for reference only. Coverage and reimbursement may vary by payer.

ICD-10-CM Diagnosis Code^{1,*}

ICD-10-CM Diagnosis Code	Description
H18.60X	Keratoconus, unspecified
H18.61X	Keratoconus, stable
H18.62X	Keratoconus, unstable
For keratoconus codes, add the appropriate sixth character to reflect the laterality of the patient's condition 1 = right eye 2 = left eye 3 = bilateral	

*ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification. The ICD-10-CM diagnosis codes provided may describe conditions that are consistent with the FDA-labeled indication for Epioxa. Additional ICD-10-CM diagnosis codes may be used to fully describe the patient's condition and associated manifestations.

National Drug Code (NDC)²

Epioxa is a clear, yellow, sterile buffered solution available as follows:

10-digit NDC	11-digit NDC	Description
25357-024-01	25357-0024-01	• One single-dose glass syringe containing 2 mL of EPIOXA HD 0.239% packaged in a foil pouch • One single-dose glass syringe containing 2 mL of EPIOXA 0.177% packaged in a foil pouch

HCPCS Drug Code³

Effective for dates of service on or after July 1, 2026, Epioxa should be reported using its permanent HCPCS code, **J2789**. Confirm any plan-specific requirements prior to billing.

HCPCS Code	HCPCS Descriptor
J2789	Riboflavin 5'-phosphate, ophthalmic solution (Epioxa HD/Epioxa), up to 2 mL

Each epithelium-on corneal cross-linking kit contains one 2 mL syringe of Epioxa HD 0.239% and one 2 mL syringe of Epioxa 0.177%. One billing unit of J2789 represents up to 2 mL. Therefore, one complete Epioxa treatment kit is reported as **2 billing units of J2789**.

CPT® Code⁴

CPT® Code	Descriptor
0402T	Collagen cross-linking of cornea, including removal of the corneal epithelium, when performed, and intraoperative pachymetry, when performed

CPT Copyright 2026 American Medical Association. All rights reserved. CPT® is a registered trademark of the American Medical Association. CPT®, Current Procedural Terminology.

Modifiers^{5,§}

Modifier	Description	Appropriate Use
RT	Right side (used to identify procedures performed on the right side of the body)	Append to HCPCS and CPT code to denote laterality of drug administration and crosslinking procedure
LT	Left side (used to identify procedures performed on the left side of the body)	Append to HCPCS and CPT code to denote laterality of drug administration and crosslinking procedure
JW	Drug amount discarded/not administered to any patient	Append to HCPCS code to denote wastage
JZ	Zero drug amount discarded/not administered to any patient	Append to HCPCS code to denote no wastage

§ Providers should follow payer-specific guidance regarding JW and JZ modifier reporting when billing J2789. If no drug is discarded, append JZ when required by payer policy. Providers should consult applicable payer requirements regarding drug wastage reporting.⁶

INDICATION: EPIOXA HD (riboflavin 5'-phosphate ophthalmic solution) 0.239% and EPIOXA (riboflavin 5'-phosphate ophthalmic solution) 0.177% are photoenhancers indicated for use in epithelium-on corneal collagen cross-linking for the treatment of keratoconus in adults and pediatric patients aged 13 years and older, in conjunction with the O₂n™ System and the Boost Goggles®. Please see Important Safety Information on the next page and accompanying [Full Prescribing Information](#) or visit [Epioxa.com](#).

DISCLAIMER

Glaukos provides this coding guide for informational purposes only and it is subject to change without notice. This guide is not an affirmative instruction as to which codes and modifiers to use for a particular service, supply, procedure, or treatment and does not constitute advice regarding coding, coverage, or payment for Glaukos products. It is the responsibility of providers, physicians, and suppliers to determine and submit appropriate codes, charges, and modifiers for products, services, supplies, procedures, or treatment furnished or rendered. Providers, physicians, and suppliers should contact their third-party payers for specific and current information on their coding, coverage, and payment policies. For further detailed product information, including indications for use, contraindications, effects, precautions, and warnings, please consult the product's Instructions for Use (IFU) or prescribing information (PI) prior to use. The information provided herein is without any other warranty or guarantee of any kind, expressed or implied, as to completeness, accuracy, or otherwise. Glaukos makes no guarantee of coverage or reimbursement.

Indication and Important Safety Information

INDICATIONS AND USAGE

EPIOXA HD (riboflavin 5'-phosphate ophthalmic solution) 0.239% and EPIOXA (riboflavin 5'-phosphate ophthalmic solution) 0.177% are photoenhancers indicated for use in epithelium-on corneal collagen cross-linking for the treatment of keratoconus in adults and pediatric patients aged 13 years and older, in conjunction with the O₂n™ System and the Boost Goggles®.

IMPORTANT SAFETY INFORMATION

Contraindications

EPIOXA HD and EPIOXA are contraindicated in patients with known hypersensitivity to benzalkonium chloride (BAC) or any ingredients in EPIOXA HD and EPIOXA. Epithelium-on corneal collagen cross-linking is contraindicated in aphakic and pseudophakic patients without a UV-blocking intraocular lens.

Warnings and Precautions

Corneal collagen cross-linking should be used with caution in patients with a history of herpetic keratitis due to the potential for reactivation of herpes keratitis.

Adverse Reactions

The most common adverse reaction was conjunctival hyperaemia (31%). Other adverse reactions, occurring in 5% to 25% of eyes included: corneal opacity (haze), photophobia, punctate keratitis, eye pain, eye irritation, increased lacrimation, corneal epithelium defect, eyelid oedema, corneal striae, visual acuity reduced, dry eye, and anterior chamber flare.

Dosage and Administration

EPIOXA HD and EPIOXA are for topical ophthalmic use. NOT for injection or intraocular use.

EPIOXA HD and EPIOXA are supplied in single-dose syringes. Discard opened syringes after use.

EPIOXA HD and EPIOXA are for use with the O₂n System and Boost Goggles only.

Refer to the O₂n System Operator's Manual and Boost Goggles User Guide for device instructions.

Please see full Prescribing Information for EPIOXA HD and EPIOXA at www.Epioxa.com.

You are encouraged to report all side effects to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also call Glaukos at 1-888-404-1644.

References: **1.** Centers for Disease Control (CDC). ICD-10-CM Files. Accessed June 19, 2026 from: <https://www.cdc.gov/nchs/icd/icd-10-cm/files.html>. **2.** Epioxa. Prescribing information. Glaukos; 2025. **3.** Centers for Medicare & Medicaid Services (CMS) Healthcare Common Procedure Coding System (HCPCS) Application Summaries and Coding Determinations. CMS. Accessed June 10, 2026. <https://www.cms.gov/files/document/2026-hcpcs-application-summary-quarter-1-2026-drugs-biologicals.pdf>. **4.** American Medical Association. Current Procedural Terminology: CPT® 2026: Professional Edition. Chicago, IL: AMA Press; 2026. **5.** Modifiers. Noridian Medicare. Accessed October 15, 2025. <https://med.noridianmedicare.com/web/jeb/topics/modifiers>. **6.** Centers for Medicare & Medicaid Services. (2024). Discarded drugs and biologicals – JW modifier and JZ modifier policy: Frequently asked questions. Medicare Program. Retrieved September 9, 2025, from <https://www.cms.gov/medicare/medicare-fee-for-service-payment/hospitaloutpatientpps/downloads/jw-modifier-faqs.pdf>.